Literature DB >> 10404214

Immunoglobulin motif DNA recognition and heterodimerization of the PEBP2/CBF Runt domain.

T Nagata1, V Gupta, D Sorce, W Y Kim, A Sali, B T Chait, K Shigesada, Y Ito, M H Werner.   

Abstract

The polyomavirus enhancer binding protein 2 (PEBP2) or core binding factor (CBF) is a heterodimeric enhancer binding protein that is associated with genetic regulation of hematopoiesis and osteogenesis. Aberrant forms of PEBP2/CBF are implicated in the cause of the acute human leukemias and in a disorder of bone development known as cleidocranial dysplasia. The common denominator in the natural and mutant forms of this protein is a highly conserved domain of PEBP2/CBF alpha, termed the Runt domain (RD), which is responsible for both DNA binding and heterodimerization with the beta subunit of PEBP2/CBF. The three-dimensional structure of the RD bound to DNA has been determined to be an S-type immunoglobulin fold, establishing a structural relationship between the RD and the core DNA binding domains of NF-kappaB, NFAT1, p53 and the STAT proteins. NMR spectroscopy of a 43.6 kD RD-beta-DNA ternary complex identified the surface of the RD in contact with the beta subunit, suggesting a mechanism for the enhancement of RD DNA binding by beta. Analysis of leukemogenic mutants within the RD provides molecular insights into the role of this factor in leukemogenesis and cleidocranial dysplasia.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10404214     DOI: 10.1038/10658

Source DB:  PubMed          Journal:  Nat Struct Biol        ISSN: 1072-8368


  30 in total

1.  MODBASE, a database of annotated comparative protein structure models.

Authors:  R Sánchez; U Pieper; N Mirković; P I de Bakker; E Wittenstein; A Sali
Journal:  Nucleic Acids Res       Date:  2000-01-01       Impact factor: 16.971

2.  Comparative protein structure modeling by iterative alignment, model building and model assessment.

Authors:  Bino John; Andrej Sali
Journal:  Nucleic Acids Res       Date:  2003-07-15       Impact factor: 16.971

3.  Auto-inhibition and partner proteins, core-binding factor beta (CBFbeta) and Ets-1, modulate DNA binding by CBFalpha2 (AML1).

Authors:  T L Gu; T L Goetz; B J Graves; N A Speck
Journal:  Mol Cell Biol       Date:  2000-01       Impact factor: 4.272

4.  Auto-inhibition of Ets-1 is counteracted by DNA binding cooperativity with core-binding factor alpha2.

Authors:  T L Goetz; T L Gu; N A Speck; B J Graves
Journal:  Mol Cell Biol       Date:  2000-01       Impact factor: 4.272

5.  Oct-1 counteracts autoinhibition of Runx2 DNA binding to form a novel Runx2/Oct-1 complex on the promoter of the mammary gland-specific gene beta-casein.

Authors:  Claire K Inman; Na Li; Paul Shore
Journal:  Mol Cell Biol       Date:  2005-04       Impact factor: 4.272

6.  New insights into transcriptional and leukemogenic mechanisms of AML1-ETO and E2A fusion proteins.

Authors:  Jian Li; Chun Guo; Nickolas Steinauer; Jinsong Zhang
Journal:  Front Biol (Beijing)       Date:  2016-09-03

Review 7.  Overview of protein structural and functional folds.

Authors:  Peter D Sun; Christine E Foster; Jeffrey C Boyington
Journal:  Curr Protoc Protein Sci       Date:  2004-05

8.  Filamin A-bound PEBP2beta/CBFbeta is retained in the cytoplasm and prevented from functioning as a partner of the Runx1 transcription factor.

Authors:  Naomi Yoshida; Takehiro Ogata; Kenji Tanabe; Songhua Li; Megumi Nakazato; Kazuyoshi Kohu; Toshiro Takafuta; Sandor Shapiro; Yasutaka Ohta; Masanobu Satake; Toshio Watanabe
Journal:  Mol Cell Biol       Date:  2005-02       Impact factor: 4.272

9.  Runx1 binds as a dimeric complex to overlapping Runx1 sites within a palindromic element in the human GM-CSF enhancer.

Authors:  Sarion R Bowers; Fernando J Calero-Nieto; Stephanie Valeaux; Narcis Fernandez-Fuentes; Peter N Cockerill
Journal:  Nucleic Acids Res       Date:  2010-05-18       Impact factor: 16.971

Review 10.  Runx3 knockouts and stomach cancer.

Authors:  Ditsa Levanon; Ori Brenner; Florian Otto; Yoram Groner
Journal:  EMBO Rep       Date:  2003-06       Impact factor: 8.807

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.